Long-Term Benefit Observed With Sotorasib in KRAS-Mutant Non-Small Cell Lung Cancer
The 2-year overall survival rate was 32.5%.
American Association for Cancer Research (AACR)
Recurrent DCIS Not Always Related to Primary Tumor
Researchers found that, in 18% of recurrences, the new tumor was molecularly unrelated to the original tumor.
Patterns of Resistance to CAR-T Therapy in Patients With Acute Lymphoblastic Leukemia
Researchers sought to determine gene regulation patterns that may help predict response to CAR-T therapy in patients with acute lymphoblastic leukemia.
Racial Disparities Noted in Treatment With Bone-Modifying Agents Among Patients With Multiple Myeloma
Researchers sought to determine if there are racial disparities in treatment with bone-modifying agents for patients with multiple myeloma.
CoVac-1 Induces T-Cell Responses in Patients With B-Cell Deficiencies
CoVac-1, a peptide-based COVID-19 vaccine, induced T-cell responses in patients with B-cell deficiencies.
Risks for Relapse Revealed in Multiethnic Study of Patients With Acute Lymphoblastic Leukemia
Researchers sought to determine risk factors for relapse in patients with ALL.
Biomarkers May Help Guide Treatment in Cancer Patients With COVID-19
Three biomarkers were associated with prognosis after COVID-19 treatment.
Predictors of Mortality During Hospital Stays in Patients With Multiple Myeloma
Researchers sought to determine the predictors of mortality during hospital stays in patients with multiple myeloma.
Combo Appears Effective After Anti-PD-1 Failure in Advanced Melanoma
Ipilimumab plus nivolumab demonstrated efficacy in a phase 2 trial of patients with advanced melanoma who failed prior anti-PD-1 therapy.
Toripalimab-Chemo Dubbed New Standard Care for Advanced Nasopharyngeal Carcinoma
Adding toripalimab to standard chemotherapy extended progression-free survival by 13.2 months.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in AACR 2022
Loading... 
Loading...